Skip to main content
MarketStoryBook
All stories207940.KS in “Drug Manufacturing De-Risks From China”207940.KS in stories207940.KS stock

207940.KS in “Drug Manufacturing De-Risks From China”

Samsung Biologics Co.,Ltd.

Bull sideFadingExposure: not rated yet

Its large-scale Korean biologics plants offer global pharmaceutical customers a credible non-Chinese alternative.

207940.KS impact map — “Drug Manufacturing De-Risks From China”

How this story travels from the headline to 207940.KS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading 207940.KS impact map…

Price history, marked with story events

Jul 20, 2026 – Oct 19, 2026 · 65 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

Drug Manufacturing De-Risks From China

Western drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.

BULL side — Its large-scale Korean biologics plants offer global pharmaceutical customers a credible non-Chinese alternative.

Read the full Drug Manufacturing De-Risks From China story

Bull side

3 stories
  • America Imports the World's Drug Prices

    207940.KS in “America Imports the World's Drug Prices”

    StableExposure: not rated yet

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Samsung Biologics combines large-scale biologics manufacturing with Samsung Bioepis's biosimilars, supporting lower-cost alternatives across blockbuster categories.

  • 207940.KS in “Drug Manufacturing De-Risks From China”

    FadingExposure: not rated yet
    Viewing

    Western drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.

    Its large-scale Korean biologics plants offer global pharmaceutical customers a credible non-Chinese alternative.

  • The Patent Cliff Sparks a Biotech Land Grab

    207940.KS in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    Demand for outsourced production of antibodies and other complex biologics should rise as acquirers seek to scale newly purchased pipelines quickly.

Bear side

0 stories

No bear-side stories for 207940.KS yet.